Try our beta test site
21 studies found for:    SGI-110
Show Display Options
Rank Status Study
1 Completed SGI-110 in Combination With Carboplatin in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: SGI-110 and carboplatin;   Drug: Treatment of Choice ( topotecan, pegylated liposomal doxorubicin, or paclitaxel)
2 Completed SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Condition: Hepatocellular Carcinoma
Intervention: Drug: SGI-110
3 Active, not recruiting SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Conditions: MDS;   CMML;   AML
Intervention: Drug: SGI-110
4 Recruiting SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS)
Condition: Leukemia
Intervention: Drug: SGI-110
5 Recruiting A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients
Condition: Metastatic Melanoma
Interventions: Drug: SGI-110;   Drug: Ipilimumab
6 Recruiting Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Conditions: Germ Cell Tumor;   Testis Cancer;   Testicular Cancer
Intervention: Drug: SGI-110
7 Active, not recruiting SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: SGI-110 (guadecitabine);   Drug: Treatment Choice
8 Recruiting Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: SGI-110
9 Active, not recruiting A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response
Condition: MDS
Intervention: Drug: SGI-110 administration
10 Recruiting SGI-110 Plus Durvalumab/Tremelimumab in SCLC
Condition: Extensive-stage Small Cell Lung Cancer
Interventions: Drug: Durvalumab;   Drug: Tremelimumab;   Drug: SGI-110
11 Recruiting 4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML)
Condition: Leukemia
Interventions: Drug: SGI-110;   Drug: Idarubicin;   Drug: Cladribine
12 Recruiting SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT)
Conditions: Leukemia;   Myeloproliferative Diseases
Interventions: Drug: SGI-110;   Procedure: Donor Lymphocyte Infusion
13 Recruiting A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
Condition: Myeloproliferative Neoplasms
Intervention: Drug: SGI-110
14 Recruiting Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer
Condition: Previously Treated Metastatic Colorectal Cancer
Interventions: Drug: SGI-110;   Drug: Irinotecan;   Drug: regorafenib;   Drug: TAS-102
15 Recruiting SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
Condition: Metastatic Colorectal Cancer
Interventions: Drug: CY;   Biological: GVAX;   Drug: SGI-110
16 Recruiting Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Conditions: Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic
Interventions: Drug: Guadecitabine;   Other: Treatment Choice
17 Recruiting Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: guadecitabine;   Drug: Treatment Choice (TC)
18 Not yet recruiting Combination Study of Guadecitabine and Pembrolizumab.
Conditions: Castration-Resistant Prostatic Cancer;   Non Small Cell Lung Cancer
Interventions: Drug: Guadecitabine;   Drug: Pembrolizumab
19 Recruiting Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Guadecitabine;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
20 Recruiting Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
Conditions: Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Interventions: Drug: Atezolizumab;   Drug: Guadecitabine

   Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.